Pliant Therapeutics raised $62 million in a second round of financing that will be used to support the development of the company’s lead product candidates in fibrotic diseases. The funding is expected to advance therapies to early-stage clinical trials in idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis…
Galapagos is planning to launch a Phase 2 clinical trial for its treatment candidate GLPG1205 in patients with idiopathic pulmonary fibrosis (IPF). Expected to begin in the second half of 2018, the PINTA trial will evaluate the safety and effectiveness of this investigational therapy at several clinical sites in…
Pulmonary fibrosis (PF) and other lung diseases may be late complications in patients with Type 2 diabetes, according to a German study. The study, “Breathlessness and Restrictive Lung Disease: An Important Diabetes-Related Feature in Patients with Type 2 Diabetes,” was published in the journal Respiration. Breathlessness…
NuMedii will collaborate with researchers at Yale School of Medicine and Brigham and Women’s Hospital to develop precision therapies and biomarkers for idiopathic pulmonary fibrosis (IPF). Under this strategic research collaboration, the company will work with teams of two leading experts in interstitial lung disease: Naftali Kaminski, MD, a…
A man with idiopathic pulmonary fibrosis (IPF) was kept alive and his blood oxygenated for more than a year while waiting for a lung transplant using a type of extracorporeal membrane oxygenation (ECMO) called veno-venous ECMO — a procedure usually limited in use to about two weeks, researchers in Japan report. They estimate that one…
Astragaloside IV — a compound isolated from a traditional Chinese medicinal plant — was found to reverse epithelial–mesenchymal transition, a process crucial to the progression of fibrosis, through its impact on a protein called FOXO3a, a study by researchers in China reports. The study, “Astragaloside IV modulates TGF-b1-dependent epithelial-mesenchymal…
The introduction of bias in the design and analysis of studies likely explains a reported reduction of mortality with antacid therapy in patients with idiopathic pulmonary fibrosis (IPF), according to a new Canadian review study. The research, “The effect of anti-acid therapy on survival in idiopathic…
Formaldehyde, a chemical widely used in construction, health, and manufacturing industries, was seen to worsen lung inflammation and fibrosis in a mouse model of pulmonary fibrosis (PF), a Brazilian study reports. In mice lungs, the chemical was found to increase the amount of collagen, a protein responsible for tissue…
A common oral medication for type 2 diabetes called metformin was seen to quickly reverse pulmonary fibrosis in a mouse model of the disease and lessen fibrosis in lung tissue of PF patients, a study reports, adding that similar compounds might have similar benefits. The research, “Metformin reverses…
Galectin Therapeutics was issued a patent for its lead investigative therapy GR-MD-02 for the treatment of pulmonary fibrosis by the U.S. Patent and Trademark Office (USPTO), the company announced. GR-MD-02 is a carbohydrate-based medicine that binds and stops the action of the galectin-3 protein, which is directly involved in multiple…
Get regular updates to your inbox.
